A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101
← catalyst calendarNCT07403188 · readout ≤ 5,279 d
Sponsored by Kyverna Therapeutics (industry) · KYTX — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
70estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-11-24 | actual | When the study began enrolling |
| Primary completion | Jan 2041 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jan 2041 | estimated | The whole study's end, after follow-up |
| First posted | 2026-02-11 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Refractory Lupus Nephritis
- Myasthaenia Gravis
- Stiff Person Syndrome
- Rheumatoid Arthritis (RA)
- Multiple Sclerosis
- Dermatomyositis
- Systemic Sclerosis (SSc)
Intervention
- Drug: KYV-101
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with treatment-related adverse events (AEs) as assessed by CTCAE v6.0 through Year 15 of long-term follow-up (LTFU).
measured Up to 15 years from study entry
Number of participants with new or recurrent malignancies as assessed by CTCAE v6.0 through Year 15 of long-term follow-up (LTFU).
measured Up to 15 years from study entry
Number of participants with new or exacerbation of a pre-existing neurologic disorder as assessed by CTCAE v6.0 through Year 15 of long-term follow-up (LTFU).
measured Up to 15 years from study entry
Number of participants with new or exacerbation of a prior rheumatologic or other autoimmune disorder as assessed by CTCAE v6.0 through Year 15 of long-term follow-up (LTFU).
measured Up to 15 years from study entry
Number of participants with new hematologic disorders as assessed by CTCAE v6.0 through Year 15 of long-term follow-up (LTFU).
measured Up to 15 years from study entry
Number of participants with new infections as assessed by CTCAE v6.0 through Year 15 of long-term follow-up (LTFU).
measured Up to 15 years from study entry
Number of participants with positive Replication-Competent Lentivirus (RCL) laboratory test results through Year 5 of long-term follow-up (LTFU).
measured Up to 5 years from study entry
Number of participants with positive Chimeric Antigen Receptor (CAR) laboratory test results through Year 5 of long-term follow-up (LTFU).
measured Up to 5 years from study entry
Number of participants with positive Anti-Drug-Antibody (ADA) laboratory test results through Year 5 of long-term follow-up (LTFU).
measured Up to 5 years from study entry
Permalink · KYTX's whole pipeline · Catalyst calendar · Every registered study · What changed